Combining the anti-inflammatory drug baricitinib with the antiviral drug remdesivir reduced the median recovery time for hospitalized COVID-19 patients from eight to seven days, according to clinical trial results published Friday in the New England Journal of Medicine.

The therapy appeared to benefit patients requiring high-flow oxygen or non-invasive ventilation most, reducing their median time to recovery from 18 days to 10 days, researchers said.

The clinical trial is the second in the National Institutes of Health Adaptive COVID-19 Treatment Trial, a study to evaluate therapeutics for people hospitalized with COVID-19. 

The Food and Drug Administration last month authorized the emergency use of baricitinib in combination with remdesivir to treat suspected or laboratory confirmed COVID-19 in certain hospitalized patients requiring supplemental oxygen, invasive mechanical ventilation or extracorporeal membrane oxygenation.

Related News Articles

Headline
The Food and Drug Administration yesterday announced that Olympus issued a global recall of its ViziShot 2 FLEX needles manufactured prior to May 12 following…
Headline
The Advisory Committee on Immunization Practices Sept. 19 recommended that patients should consult their health care provider if they want to receive a COVID-…
Headline
The Department of Health and Human Services Sept. 18 announced it will take new actions to help improve care for individuals with long COVID. They include a…
Headline
The Food and Drug Administration has identified a Class I recall for Mo-Vis BVBA R-net Joysticks due to a firmware error that causes the wheelchair to ignore…
Headline
The Centers for Disease Control and Prevention is predicting a similar combined number of peak hospitalizations from COVID-19, the flu and respiratory…
Headline
The Occupational Safety and Health Administration today announced a 60-day extension of the comment period on its proposed rule to remove the remaining…